Needham analyst Michael Matson (NYSE:MATX) reiterated a Buy rating on Resmed (NYSE:RMD) on Tuesday, setting a price target of $229, which is approximately 17.59% above the present share price of $194.74.
Matson expects Resmed to post earnings per share (EPS) of -$0.54 for the second quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in Resmed, with an average price target of $234.5.
The analysts price targets range from a high of $240 to a low of $229.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $768.77 million and a net profit of $223.43 million. The company's market cap is $28.34 billion.
According to TipRanks.com, Needham analyst Michael Matson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 17.9% and a 69.97% success rate.
Founded in 1989, California-based ResMed, Inc. is a medical equipment company. The company is engaged in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through two segments: Sleep and Respiratory Care, and SaaS (Software as a Service).